Longleaf Partners BIO trades
Mason Hawkins
Mason Hawkins Bio-Rad Laboratories Inc stake
total: 53
Trades details
- Total transactions:
- 6
- New positions:
- 1
- Sold out:
- 1
- Added:
- 2
- Reduced:
- 2
- Held since:
- 2023 Q2
- Held for:
- 12 quarters
- Latest activity:
- 2026 Q2
According to 2026 Q2 report, Mason Hawkins doesn't hold any Bio-Rad Laboratories Inc (BIO) shares. To date, the estimated cost basis is nearly $358.72 for "buy" trades and estimated average "sell" price is $282.29. Longleaf Partners first purchased BIO in 2023 Q2, initially acquiring 171,987 shares. Since the initial investment in Bio-Rad Laboratories Inc (BIO), Longleaf Partners has made 5 more transactions.
When did Mason Hawkins sell Bio-Rad Laboratories Inc (BIO)?
Mason Hawkins sold off the entire Bio-Rad Laboratories Inc (BIO) position in 2026 Q2.
When did Mason Hawkins buy Bio-Rad Laboratories Inc (BIO)?
Mason Hawkins first invested in Bio-Rad Laboratories Inc (BIO) in 2023 Q2 at the reported quarter-end price of $379.12 per share.
What's the cost basis of Longleaf Partners's BIO stake?
The estimated cost basis for Bio-Rad Laboratories Inc (BIO) stake is around $358.72 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $358.72
- Weighted AVG sell price:
- $282.29
Mason Hawkins's historical trades in Bio-Rad Laboratories Inc
6 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q2
|
0.00%
|
0
|
$278.75
|
|
-100% (-140,913)
|
-3.73%
|
|
2025 Q4
|
3.89%
|
140,913
|
$302.99
|
$42,695,230
|
-16.90% (-28,666)
|
-0.77%
|
|
2025 Q3
|
4.20%
|
169,579
|
$280.39
|
$47,548,256
|
-22.80% (-50,088)
|
-1.19%
|
|
2025 Q1
|
4.60%
|
219,667
|
$243.56
|
$53,502,095
|
+11.52% (+22,698)
|
+0.48%
|
|
2023 Q4
|
4.65%
|
196,969
|
$322.89
|
$63,599,320
|
+14.53% (+24,982)
|
+0.59%
|
|
2023 Q2
|
4.75%
|
171,987
|
$379.12
|
$65,203,711
|
new
|
+4.75%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.